Zhejiang Shengda Bio-Pharm Co., Ltd. (SHA:603079)
12.70
-0.38 (-2.91%)
Sep 10, 2026, 3:00 PM CST
SHA:603079 Revenue
Zhejiang Shengda Bio-Pharm had revenue of 199.84M CNY in the quarter ending June 30, 2026, a decrease of -1.67%. This brings the company's revenue in the last twelve months to 832.86M, down -1.28% year-over-year. In the year 2025, Zhejiang Shengda Bio-Pharm had annual revenue of 844.54M with 2.07% growth.
Revenue (ttm)
832.86M
Revenue Growth
-1.28%
P/S Ratio
2.86
Revenue / Employee
769.03K
Employees
1,083
Market Cap
2.38B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 844.54M | 17.13M | 2.07% |
| Dec 31, 2024 | 827.40M | 100.00M | 13.75% |
| Dec 31, 2023 | 727.41M | -10.61M | -1.44% |
| Dec 31, 2022 | 738.02M | -51.71M | -6.55% |
| Dec 31, 2021 | 789.73M | -77.58M | -8.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Fengyuan Pharmaceutical | 3.50B |
| ShanXi C&Y Pharmaceutical Group Co.,LTD. | 849.67M |
| Enwei Pharmaceutical | 826.13M |
| Jiangxi Synergy Pharmaceutical | 784.40M |
| Hainan Huluwa Pharmaceutical Group | 634.04M |
| Chengdu huasun technology group Inc. , LTD. | 486.70M |
| Zhejiang Shapuaisi Pharmaceutical | 423.20M |
| Tuoxin Pharmaceutical Group | 407.75M |